Boston Scientific launches TAVI registry study for Lotus heart valve

Boston Scientific says it's launched a post-market registry study for its Lotus replacement heart valve.

Boston Scientific (NYSE:BSX) said it's launched a post-market registry study for its Lotus replacement heart valve, aiming to follow patients implanted with the transcatheter aortic heart valve out to 5 years.

Boston Scientific

News Well, Clinical Trials, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1tLxrCo